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Abstract
Background: The helix-loop-helix transcription factor Id-1 (an inhibitor of differentiation and
DNA binding) plays a role in development and progression of many tumours. Id-1 is known to exert
its effects on the epidermal growth factor receptor (EGFR) and the vascular endothelial growth
factor (VEGF). The aim of this study was to reveal whether there was a relationship between Id-1
and EGFR and VEGF in colorectal carcinoma.
Methods: Tumour and non-tumour tissue specimens from 46 cases of colorectal carcinoma were
exposed to immunohistochemical staining for Id-1, EGFR and VEGF. The relationship between the
degree of staining and tumour grade, tumour stage and all tumour markers was investigated.
Results: Tumour cells showed positive staining for Id-1 in 43 cases (93.5%), for EGFR in 41 cases
(89%) and for VEGF in 42 cases (91%). There was a significant relation between the tumour grade
and the degree of staining for Id-1, EGFR and VEGF. The relation between the tumour stage and
the degree of staining for Id-1, EGFR and VEGF was also significant. There was a significant relation
between Id-1 expression and EGFR and VEGF expressions. Non-tumoural tissue specimens were
not stained with Id-1 and EGFR antibodies in any of the cases, but stained with VEGF antibody in 3
cases.
Conclusion:  This study revealed that Id-1, EGFR and VEGF took part in development and
progression of colorectal carcinomas and that Id-1 was associated with regulations of EGFR and
VEGF. The results of this study support the idea that not only EGFR and VEGF but also Id-1 could
be new targets in cancer treatment.
Background
Colorectal carcinomas are frequently encountered
tumours in the world, especially in developed countries.
These tumours account for about 10% of deaths from can-
cer [1]. They were the second and the third most frequent
causes of deaths from cancer in males and females respec-
tively. The conventional treatment for colorectal tumours
is surgery. Adjuvant treatment is employed for advanced
stage tumours.
It is known that tumour grade, penetration depth, angiol-
ymphatic invasion and lymph node involvement are
important conventional parameters used to determine the
prognosis in colorectal tumours [2]. However, his-
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topathological parameters do not exactly show the prog-
nosis in some cases and therefore, additional prognostic
factors are needed. In recent years, there have been many
studies on new markers to predict the prognosis and to
determine tumours resistant to treatment.
It has been reported that epidermal growth factor receptor
(EGFR) expression is associated with tumour prolifera-
tion, angiogenesis and invasiveness in many tumours [3].
One of those tumours is colorectal carcinoma [4]. In fact,
EGFR has been shown to play a role in tumour develop-
ment and progression [4,5]. In addition, several studies
showed a relationship between high EGFR levels and high
grade tumours and poor prognosis [5,6]. The studies on
EGFR have suggested that EFGR can be a new target mol-
ecule in anticancer treatments.
Angiogenesis has a critical role in tumour progression.
There are many factors known to be associated with ang-
iogenesis. Vascular endothelial growth factor (VEGF), the
most important and most extensively studied factor, is
known to be associated with many tumours [7]. VEGF has
been shown to be associated with the extent and the stage
of colorectal carcinomas [8].
Several studies, however, have revealed that VEGF is not
an independent prognostic factor in colorectal carcino-
mas [8,9]. The Id (an inhibitor of differentiation/DNA
binding) protein family, a group of basic helix-loop-helix
transcription factors, has been shown to be involved in
carcinogenesis and a prognostic marker in several types of
human cancers [10-16]. Id-1 does not have a basic
domain for DNA binding and it forms heterodimers and
acts as a dominant inhibitor of simple helix-loop-helix
transcription factors [17,18]. Id-1 has been shown to play
a critical role in cell proliferation, differentiation and
senescence. It has been claimed to play a key role in cancer
progression, but its molecular mechanism has not been
understood yet. Increased Id-1 expression has been found
to be associated with advanced stage tumours and poor
prognosis. In addition, ovarian cancer patients with
increased Id-1 levels have shorter survival than those with
low Id-1 expression [19]. High Id-1 levels have been
shown to be associated with more than 20 types of cancer
including breast, prostate, cervical, liver and endometrial
cancer [20-26]. It has been shown that Id-1 is constitu-
tively expressed in aggressive cells in breast cancers [11].
High Id-1 levels have also been found to accompany high
grade and invasive endometrial cancers [22]. Increased Id-
1 levels have been considered as the indicator of more
aggressive clinical behaviour in breast and cervical cancers
[11,14-16]. It has also been demonstrated that increased
Id-1 levels are accompanied by high Gleason scores in
prostate cancers [27]. These results indicate that Id-1 may
be involved in not only carcinogenesis but also several
types of cancer.
Recently, it has been proposed that Id-1 is a regulator in
the EGFR and VEGF pathway [28-30]. Id-1 mediated can-
cer cell growth has been shown to be associated with
EGFR activation in ovarian and prostate cells [19,24].
Both Id-1 and EGFR levels have been found to be high in
bladder cancers [29]. These results indicate that Id-1 plays
a role in cancer cell growth through positive regulation of
the EGFR signalling pathway. It has been reported that
overexpression of Id-1 in prostate cancer cells play a role
in angiogenesis whereby VEGF activation [30]. Id-1 sup-
pression, however, has been found to down-regulate
VEGF in hepatocellular carcinoma [20].
In the light of all above mentioned studies, one can con-
clude that Id-1 has an important role in progression of
many tumours. However, there have been few studies on
the role of Id-1 in colorectal carcinoma [10,31]. Those few
studies have revealed that Id-1 is involved in tumour pro-
gression and associated with poor prognostic factors, but
the relationship between Id-1 and EGFR and VEGF has
not been studied. In this study, using immunohistochem-
ical methods, we investigated the relationship between Id-
1 and such well-known prognostic factors as tumour
grade and tumour stage and such molecules as EGFR and
VEGF.
Methods
Patients
This study included 51 patients who underwent surgery
for colorectal cancer in Adnan Menderes University Hos-
pital between 2002 and 2006. Five patients were excluded
from the study since data about those patients were
incomplete. Data about sex, age, tumour size, TNM and
Dukes' stage were obtained from all patients. None of the
cases received treatment for cancer before surgery. All
specimens were re-evaluated before the current study by
two pathologists. Paraffin-embedded specimens that con-
tained normal colonic tissue together with tumour tissue
were selected for immunohistochemical analysis.
Immunohistochemistry
First, sections 4 μm in thickness from selected paraffin
embedded blocks were placed on positively charged
slides. Second, all of the specimens were deparafinized
with xylene and rehydrated with ethanol and then all were
washed in 0.1% Tris-buffered saline (TBS) for five min
three times. Third, they were kept in 0.3% hydrogen per-
oxidase for 20 minutes for the blockage of endogenous
peroxidase activity and the sections were rinsed in TBS for
five min three times. Fourth, for antigen retrieval, the
slides were placed in sodium citrate buffer and left in a
microwave oven at 700-W for 10 minutes. After cooling toJournal of Experimental & Clinical Cancer Research 2008, 27:69 http://www.jeccr.com/content/27/1/69
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room temperature and washing with TBS for five min
three times, non-specific binding was blocked with 10%
normal rabbit serum for 1 hour. Fifth, they were incu-
bated with primary antibodies Id-1 (1:400 dilution, Santa
Cruz Biotechnology, Santa Cruz, CA, USA), VEGF (ready-
to-use solution, RB-9031; NeoMarkers, Fremont, CA,
USA) and EGFR (ready-to-use solution, MS-378; NeoMar-
kers, Fremont, CA, USA) for 1 hour. Sixth, after these the
slides were rinsed with TBS for five min three times, they
were exposed to biotin free horseradish peroxidase (HRP)
enzyme-labelled polymer (EnVision plus the detection
system, ChemMateTM EnVision +/HRP Rb&Mo, DAKO,
Hamburg, Germany). Thirty minutes later, the slides were
rinsed again in TBS for five min three times. Then 3,3'-
diaminobenzidine (DAKO) chromogen substrate was
added. Last, the slides were rinsed under tap water and
countered with Mayer's haematoxylin, dehydrated and
mounted. For the negative control, the slides were incu-
bated with TBS without primary antibody. The slights
known to be positively immunostained were used as pos-
itive controls.
Evaluation of the immunostaining
The slides were examined at low magnification (×100)
and areas containing the highest degree of staining were
considered as "hot spot" areas and evaluated at high mag-
nification (×200). The staining cell ratio was determined
by counting at least 200 cells. When 10% or more than
10% of the cells were stained with all the markers, staining
was considered positive. The staining degree in different
magnifications were evaluated as in the following: "weak"
staining visible at × 200, "moderate" staining visible at ×
100 and "strong" staining visible at × 40.
Statistical analysis
All statistical analyses were performed with SPSS (Win-
dows version 13.0, SPSS Inc. Chicago, IL, USA). χ2 and
Mann-Whitney U-test were used to compare the parame-
ters tested and Spearman's correlation analysis was used
to determine the relation between immunohistochemical
markers. P < 0.05 was considered significant.
Results
The patients' clinicopathologic characteristics are summa-
rized in Table 1.
Staining for Id-1, EGFR and VEGF in Tumoural and Non-
tumoural Tissues
Out of 46 cases, 43 (93.5%) had positive cytoplasmic
staining with Id-1 antibody. Most of them had moderate
to strong staining. Forty-one cases (89%) had moderate to
strong staining with EGFR antibody in the cytoplasm and
cell membranes. Forty-two cases (91%) had moderate to
strong staining with VEGF antibody. There was no stain-
ing with Id-1 and EGFR antibodies in non-tumoural tis-
sues, but there was stromal staining with VEGF antibody
in three cases (Figure 1A–E–I).
Relationships between Tumour Grades and Id-1, EGFR and 
VEGF
In order to investigate the relation between colorectal
tumour grades and Id-1, EGFR and VEGF, the tumours
were divided into three groups: grade I (G I) (n = 10),
grade II (G II) (n = 21) and grade III (G III) (n = 15)
tumours. Most of the cancer specimens had positive stain-
ing for Id-1, EGFR and VEGF. G III tumours had the high-
est degree of staining for Id-1, while the degree of staining
was lower in G I tumours. As a result, there was a signifi-
cant difference in Id-1 expression between G I and II
tumours (p = 0.005) and between G II and III tumours (p
= 0.0012) (Figure 1B–C–D). The degrees of staining with
EGFR and VEGF antibodies were very similar to the degree
of staining with Id-1 antibody and as tumour grade
increased so did the degree of staining. There was also a
significant difference in EGFR (Figure 1F–G–H) and VEGF
(Figure 1J–K–L) expressions between G I and II tumours
(p = 0.02 and p = 0.05, respectively) and between G II and
III tumours (p = 0.01 and p = 0.04, respectively) (Table 2).
Relationships between Tumour Stages and Id-1, EGFR and 
VEGF
In order to investigate the relation between tumour stages
and staining with Id-1, EGFR and VEGF antibodies, the
tumours were divided into two groups based on Dukes'
classifications: Group 1 (Dukes' stage A+B, n = 19) and
Group 2 (Dukes stage C+D, n = 27). The degree of staining
for Id-1 was significantly higher in Group 2 than in Group
1 (p = 0.018). Similarly, EGFR and VEGF expressions were
Table 1: Patients characteristics (n = 46)
n (%)
Age (year)
Range 33–94
Median 62
Sex
Male 29 (63)
Female 17 (37)
Dukes' stage
A 7 (15.2)
B 12 (26.1)
C 11 (23.9)
D 16 (34.8)
Grade
G1 10 (21.7)
G2 21 (45.7)
G3 15 (32.6)Journal of Experimental & Clinical Cancer Research 2008, 27:69 http://www.jeccr.com/content/27/1/69
Page 4 of 7
(page number not for citation purposes)
significantly higher in high stage tumours than low stage
tumours (p = 0.03 and p = 0.04, respectively) (Table 2).
Relationships between Id-1, EGFR and VEGF Expressions
Id-1 expression was significantly correlated with EGFR
expression (r = 0.540, p = 0.002) and VEGF expression (r
= 0.737, p = 0.0001). However, there was no significant
difference between EGFR and VEGF expressions.
Discussion
Colorectal cancer was the second most frequent cause of
death in men and the third most frequent cause of death
in women [1]. Colorectal carcinomas are more frequent in
developed countries and there have been a lot of studies
on the disease. The studies have focused on such issues
that help to predict the prognosis and provide guidance in
treatment. There is strong evidence that EGFR and VEGF
play a role in carcinogenesis and progression in many
human cancers. Recent studies seeking new treatment
alternatives for advanced stage tumours have shown that
EGFR and VEGF are new targets [32,33]. Id-1, a negative
regulator of basic helix-loop-helix transcription factors,
plays an important role in the regulation of cell prolifera-
tion and differentiation. Id-1 is itself not a transcription
factor, but involved in regulation of many regulatory pro-
teins [17]. Although Id-1 is thought to play a role in tum-
origenesis and can be a new therapeutic target, it is not
clear how it affects molecular mechanisms in various
tumours. There have been a few studies on the relation
between Id-1 and colorectal carcinoma [10,31]. However,
to our knowledge, this study was the first to show a rela-
tion between Id-1 and EGFR and VEGF in colorectal can-
cers.
It is known that EGFR is involved in carcinogenesis in
many tumours. It plays a role in many events such as
tumour proliferation, angiogenesis and invasiveness [3-
6]. While some studies have revealed that EGFR is associ-
ated with poor prognosis in colon cancers, other studies
have shown that there is no relationship between EGFR
and survival [3]. We found that EGFR was significantly
associated with high grade and high stage tumours. This
finding indicates a role of EGFR in tumour progression.
Differential staining intensity of Id-1, EGFR and VEGF between non-tumoural colorectal tissues and colorectal carcinoma spec- imens (A-E-I) Figure 1
Differential staining intensity of Id-1, EGFR and VEGF between non-tumoural colorectal tissues and colorectal 
carcinoma specimens (A-E-I). 2-Images of Id-1 (B-C-D), EGFR (F-G-H) and VEGF (J-K-L) expressions in different grades of 
colorectal carcinoma. Note that increased Id-1, EGFR and VEGF expressions are associated with increased tumour grade.Journal of Experimental & Clinical Cancer Research 2008, 27:69 http://www.jeccr.com/content/27/1/69
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Like EGFR, Id-1 has been shown to have an up-regulation
in many tumours [19,24]. Increased Id-1 levels are associ-
ated with poor prognosis in advanced stage tumours
[22,23,27]. It has been reported that Id-1 did not have an
activity in normal tissue in some tumours, but was only
expressed in cancer cells [28]. Therefore, it has been sug-
gested that Id-1 can be considered as an oncogene. There
have been many studies showing a relationship between
Id-1 and EGFR in many types of cancer. Studies on pros-
tate cancer, ovarian cancer and renal cell carcinoma
showed high Id-1 levels to be correlated with high EGFR
levels [19,24,28]. Zhang et al. reported that Id-1 inactiva-
tion suppressed EGFR expression in ovarian cancer cells
[19]. These findings have suggested that Id-1 may play a
role in the regulation of EGFR. Consistent with the results
of previous studies, this study revealed that increased Id-1
expression was correlated with high grade and advanced
stage tumours and that Id-1 expression was also signifi-
cantly associated with EGFR expression. The significant
association between high Id-1 levels and high EGFR levels
suggested a coactivation of EGFR and Id-1. It is thought
that EGFR is one of the newest therapeutic targets for
many tumours. Galizia et al. reported that antiEGFR
chemotherapeutics could be used as an adjuvant therapy
in EGFR positive colon cancer patients [35]. The finding
that Id-1 plays a role in the EGFR pathway, an alternative
likely to be used in advanced colorectal cancers, indicates
a new therapeutic target.
Angiogenesis is of great importance in cancer progression.
Many angiogenic molecules have been described and the
most important and the most extensively studied of all is
VEGF. VEGF is a key molecule in normal and abnormal
angiogenesis. It is known that many factors play a role in
regulation of VEGF. VEGF in tumoral and non-tumoral
tissues is mainly regulated by hypoxia. Apart from
hypoxia, many cytokines, hormones and growth factor
regulates VEGF expression in various tissues. Many factors
such as EGF, TGF-Beta, IL-1alpha, Insulin-like growth fac-
tors (IGFs), TSH and ACTH are autocrine and paracrine
regulators of VEGF expression. VEGF has been shown to
be involved in many types of cancer [7]. Although it has
been reported to be associated with poor prognosis in
many types of cancer, there is not an agreement about its
association with poor prognosis in colorectal cancers
[8,9]. There is a general agreement that VEGF expression is
an indicator of poor prognosis. Although there have been
many studies about VEGF, VEGF regulated mechanisms
have not been understood well. In this study, VEGF was
significantly associated with high grade and advanced
stage colorectal cancer. It turned out to contribute to
tumour progression. There have been few studies showing
a relation between Id-1 and VEGF. Those studies revealed
Table 2: Association between Id-1, EGFR, VEGF, tumour grade and Dukes' stage.
Grade Dukes' Stage
G1(n = 10) G2 (n = 21) G3 (n = 15) A+B (n = 19) C+D (n = 27)
Id-1
Absent 2 (20%) 1 (4.8%) 0 (0%) 3 (15.8%) 0 (0%)
Weak 3 (30%) 9 (42.8%) 1 (6.7%) 2 (10.6%) 3 (11.1%)
Moderate 5 (50%) 8 (38.1%) 5 (33.3%) 6 (31.5%) 10 (37%)
Strong 0 (0%) 3 (14.3%) 9 (60%) 8 (42.1%) 14 (51.9%)
p-value p = 0.005 (G1 versus G2) p = 0.0012 (G2 versus G3) p = 0.018
EGFR
Absent 3 (30%) 2 (9.5%) 0 (0%) 5 (26.4%) 0 (0%)
Weak 3 (30%) 8 (38.1%) 2 (13.3%) 3 (15.8%) 5 (18.6%)
Moderate 3 (30%) 7 (33.3%) 3 (20%) 4 (21%) 9 (33.3%)
Strong 1 (10%) 4 (19.1%) 10 (66.7%) 7 (36.8%) 3 (48.1%)
p-value p = 0.002 (G1 versus G2) p = 0.001 (G2 versus G3) p = 0.03
VEGF
Absent 3 (30%) 1 (4.7%) 0 (0%) 4 (21%) 0 (0%)
Weak 2 (20%) 7 (33.3%) 1 (6.7%) 3 (15.8%) 5 (18.6%)
Moderate 2 (20%) 8 (38.1%) 3 (20%) 5 (26.4%) 10 (37%)
Strong 3 (30%) 5 (23.9%) 11 (73.3%) 7 (36.8%) 12 (44.4%)
p-value p = 0.05 (G1 versus G2) p = 0.04 (G2 versus G3) p = 0.04Journal of Experimental & Clinical Cancer Research 2008, 27:69 http://www.jeccr.com/content/27/1/69
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a correlation between increased Id-1 levels and increased
VEGF levels in hepatocellular carcinoma and prostate car-
cinoma [20,30]. However, the role of Id-1 in angiogenesis
has not been clearly understood yet. There have been
studies showing that Id-1 leads to transcriptional activa-
tion of VEGF whereby stabilization of hypoxia inducible
factor-1alpha (HIF-1alpha) protein [20,36]. In this study,
high Id-1 expression was significantly associated with
high VEGF expression in colorectal carcinomas, which is
consistent with the results of the previous studies on dif-
ferent types of tumours. Like EGFR, VEGF is a new thera-
peutic target [7]. Although it is still debatable whether
angiogenesis affects advanced colorectal carcinomas, we
found that increased angiogenesis, shown by VEGF, con-
tributed to tumour progression and that Id-1 was associ-
ated with VEGF in colorectal carcinomas. Our study
revealed that Id-1, not alone but in combination with
other factors, play a role in VEGF activation. Further stud-
ies are needed to elucidate complex relationships of fac-
tors in tumour angiogenesis.
There have been few studies showing the role of Id-1 in
colorectal carcinoma. Wilson et al. reported that Id pro-
teins increased in cancerous tissue in cases of colorectal
cancer and that increased Id proteins were associated with
mitotic index and p53 expression [31]. Zhao et al. found
marked Id-1 expression in cancer cells in cases of colorec-
tal carcinoma compared to normal mucosa and adeno-
mas [10]. They reported that Id-1 expression was higher
when Dukes' stage increased and when there was a lymph
node metastasis. Likewise, in this study, Id-1 expression
was associated with poor prognostic factors. In addition,
no Id-1 expression was detected in the normal colon
mucosa neighbouring the tumour. These findings support
the idea that Id-1 played a role in the induction and pro-
gression of colorectal carcinoma.
Conclusion
Increased Id-1 expression was associated with high grade
and advanced stage colorectal carcinomas, which sug-
gested that Id-1 could be used as a prognostic indicator. As
far as we know, this is the first study to show that Id-1
expression was significantly associated with EGFR and
VEGF in colorectal carcinomas. The finding that Id-1 had
effects on the molecules EGFR and VEGF in colorectal car-
cinomas is important in that these two molecules have
been considered as new therapeutic targets for many
advanced tumours recently. Detection of new proteins
such as Id-1 exerting their effects on both EGFR and VEGF
will reveal alternative therapeutic targets. When these
molecules are used in treatment, the pathways such as
EGFR and VEGF contributing to tumour progression
through different mechanisms will be kept under control
by a single therapeutic agent. In addition, absence of Id-1
in non-tumoural tissues suggests that systemic chemo-
therapeutic agents may not affect normal cells and that
toxic damage due to chemotherapy may not occur. How-
ever, further studies are needed to confirm the results of
this study. The immunohistochemical technique we used
in this study is simple and inexpensive and allows deter-
mining important molecules likely to be prognostic indi-
cators and new therapeutic targets. If used frequently,
evaluation criteria will be developed and more research
on these indicators likely to be used in routine pathology
reports will be made.
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